 Kent Hutchison
Concepts (548)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 65 | 2023 | 804 | 10.540 |
Why?
| | Alcohol Drinking | 48 | 2024 | 818 | 7.160 |
Why?
| | Cues | 38 | 2018 | 315 | 5.150 |
Why?
| | Brain | 54 | 2024 | 2669 | 4.740 |
Why?
| | Cannabidiol | 12 | 2025 | 119 | 4.360 |
Why?
| | Ethanol | 31 | 2021 | 608 | 3.860 |
Why?
| | Cannabis | 21 | 2025 | 488 | 3.820 |
Why?
| | Alcohol-Related Disorders | 17 | 2021 | 124 | 3.710 |
Why?
| | Dronabinol | 16 | 2025 | 229 | 3.450 |
Why?
| | Magnetic Resonance Imaging | 59 | 2024 | 3566 | 3.140 |
Why?
| | Tobacco Use Disorder | 15 | 2021 | 252 | 2.970 |
Why?
| | Marijuana Abuse | 16 | 2024 | 233 | 2.800 |
Why?
| | Smoking | 30 | 2019 | 1633 | 2.700 |
Why?
| | Cannabinoids | 8 | 2022 | 161 | 2.520 |
Why?
| | Substance-Related Disorders | 19 | 2023 | 1072 | 2.490 |
Why?
| | Receptors, Dopamine D2 | 10 | 2018 | 98 | 2.280 |
Why?
| | Behavior, Addictive | 14 | 2021 | 82 | 2.230 |
Why?
| | Gray Matter | 7 | 2023 | 80 | 2.100 |
Why?
| | Adult | 136 | 2025 | 37616 | 1.980 |
Why?
| | Hallucinogens | 5 | 2025 | 105 | 1.950 |
Why?
| | Nerve Net | 10 | 2023 | 258 | 1.930 |
Why?
| | Brain Mapping | 14 | 2023 | 504 | 1.850 |
Why?
| | Reward | 11 | 2018 | 243 | 1.780 |
Why?
| | Varenicline | 4 | 2017 | 25 | 1.760 |
Why?
| | Polymorphism, Genetic | 14 | 2012 | 657 | 1.730 |
Why?
| | Marijuana Smoking | 7 | 2021 | 250 | 1.650 |
Why?
| | Neuroimaging | 9 | 2024 | 263 | 1.650 |
Why?
| | Receptors, Dopamine D4 | 11 | 2011 | 26 | 1.630 |
Why?
| | Male | 149 | 2025 | 67361 | 1.560 |
Why?
| | Naltrexone | 12 | 2019 | 97 | 1.520 |
Why?
| | Substance Withdrawal Syndrome | 13 | 2019 | 179 | 1.520 |
Why?
| | Genotype | 24 | 2014 | 1919 | 1.490 |
Why?
| | Executive Function | 5 | 2020 | 448 | 1.470 |
Why?
| | Female | 150 | 2025 | 72840 | 1.470 |
Why?
| | Young Adult | 59 | 2025 | 13126 | 1.470 |
Why?
| | Flowers | 4 | 2024 | 64 | 1.450 |
Why?
| | White Matter | 3 | 2021 | 145 | 1.420 |
Why?
| | Mindfulness | 2 | 2023 | 117 | 1.410 |
Why?
| | Humans | 198 | 2025 | 136783 | 1.390 |
Why?
| | Reflex, Startle | 9 | 2005 | 65 | 1.360 |
Why?
| | DNA Methylation | 9 | 2018 | 644 | 1.330 |
Why?
| | Alcoholic Intoxication | 5 | 2021 | 66 | 1.290 |
Why?
| | Central Nervous System Depressants | 10 | 2018 | 85 | 1.240 |
Why?
| | Gyrus Cinguli | 7 | 2017 | 87 | 1.170 |
Why?
| | Narcotic Antagonists | 9 | 2019 | 178 | 1.150 |
Why?
| | Polymorphism, Single Nucleotide | 27 | 2018 | 2190 | 1.140 |
Why?
| | Cigarette Smoking | 3 | 2018 | 101 | 1.130 |
Why?
| | Middle Aged | 68 | 2024 | 33200 | 1.130 |
Why?
| | Affect | 14 | 2024 | 293 | 1.110 |
Why?
| | Receptors, Opioid, mu | 6 | 2018 | 74 | 1.090 |
Why?
| | Marijuana Use | 6 | 2025 | 203 | 1.090 |
Why?
| | Taste | 5 | 2018 | 229 | 1.070 |
Why?
| | Receptor, Cannabinoid, CB1 | 5 | 2012 | 45 | 1.060 |
Why?
| | Alcoholic Beverages | 3 | 2017 | 28 | 1.050 |
Why?
| | Smoking Cessation | 10 | 2017 | 446 | 1.040 |
Why?
| | Receptors, Nicotinic | 5 | 2014 | 335 | 1.040 |
Why?
| | Medical Marijuana | 4 | 2025 | 117 | 1.030 |
Why?
| | Motivation | 14 | 2015 | 563 | 1.020 |
Why?
| | Functional Neuroimaging | 9 | 2017 | 56 | 1.010 |
Why?
| | Impulsive Behavior | 9 | 2017 | 149 | 1.000 |
Why?
| | Toll-Like Receptor 4 | 2 | 2018 | 273 | 0.980 |
Why?
| | Cognitive Neuroscience | 1 | 2025 | 10 | 0.960 |
Why?
| | Esthetics | 1 | 2025 | 51 | 0.940 |
Why?
| | Eicosanoids | 1 | 2025 | 62 | 0.930 |
Why?
| | Amidohydrolases | 3 | 2009 | 31 | 0.920 |
Why?
| | Nicotine | 12 | 2019 | 336 | 0.920 |
Why?
| | Arousal | 6 | 2018 | 156 | 0.920 |
Why?
| | Nicotinic Agonists | 6 | 2017 | 130 | 0.910 |
Why?
| | Minisatellite Repeats | 9 | 2011 | 42 | 0.880 |
Why?
| | Taste Perception | 3 | 2015 | 31 | 0.850 |
Why?
| | DNA Copy Number Variations | 4 | 2012 | 182 | 0.840 |
Why?
| | Benzodiazepines | 6 | 2014 | 152 | 0.840 |
Why?
| | Phenotype | 12 | 2015 | 3199 | 0.780 |
Why?
| | Cerebral Cortex | 9 | 2022 | 434 | 0.770 |
Why?
| | Risk-Taking | 5 | 2021 | 348 | 0.770 |
Why?
| | Anti-Inflammatory Agents | 1 | 2025 | 495 | 0.730 |
Why?
| | Parietal Lobe | 4 | 2014 | 59 | 0.720 |
Why?
| | Irritable Bowel Syndrome | 2 | 2019 | 26 | 0.720 |
Why?
| | Exercise | 8 | 2023 | 2038 | 0.680 |
Why?
| | Sensation Disorders | 1 | 2020 | 34 | 0.670 |
Why?
| | Antipsychotic Agents | 3 | 2014 | 192 | 0.650 |
Why?
| | Psychotherapy, Brief | 2 | 2011 | 34 | 0.650 |
Why?
| | Dopamine | 5 | 2013 | 300 | 0.630 |
Why?
| | Psychomotor Performance | 5 | 2013 | 312 | 0.630 |
Why?
| | Food | 3 | 2017 | 159 | 0.630 |
Why?
| | Genetic Variation | 5 | 2012 | 985 | 0.620 |
Why?
| | Motor Activity | 3 | 2013 | 719 | 0.610 |
Why?
| | Adolescent | 42 | 2024 | 21463 | 0.610 |
Why?
| | Models, Biological | 3 | 2015 | 1769 | 0.610 |
Why?
| | Exons | 2 | 2011 | 349 | 0.600 |
Why?
| | Genetic Predisposition to Disease | 6 | 2013 | 2417 | 0.600 |
Why?
| | Diffusion Tensor Imaging | 3 | 2015 | 79 | 0.600 |
Why?
| | Self Report | 6 | 2021 | 825 | 0.590 |
Why?
| | Plant Extracts | 1 | 2020 | 200 | 0.590 |
Why?
| | Stress, Psychological | 5 | 2012 | 1098 | 0.590 |
Why?
| | Double-Blind Method | 16 | 2024 | 1981 | 0.570 |
Why?
| | Severity of Illness Index | 8 | 2018 | 2831 | 0.560 |
Why?
| | Gastrointestinal Tract | 1 | 2019 | 193 | 0.540 |
Why?
| | Drinking | 1 | 2017 | 42 | 0.540 |
Why?
| | Receptors, GABA-A | 2 | 2009 | 141 | 0.540 |
Why?
| | Decision Making | 4 | 2018 | 896 | 0.540 |
Why?
| | Exploratory Behavior | 4 | 2009 | 91 | 0.530 |
Why?
| | Oxygen | 7 | 2013 | 933 | 0.530 |
Why?
| | Mental Disorders | 6 | 2025 | 1075 | 0.520 |
Why?
| | Saliva | 3 | 2019 | 241 | 0.520 |
Why?
| | Craving | 5 | 2023 | 39 | 0.510 |
Why?
| | Catechol O-Methyltransferase | 3 | 2011 | 17 | 0.510 |
Why?
| | Sex Characteristics | 6 | 2021 | 763 | 0.510 |
Why?
| | Nerve Fibers, Myelinated | 2 | 2013 | 47 | 0.510 |
Why?
| | Brain Injuries, Traumatic | 2 | 2021 | 358 | 0.510 |
Why?
| | Corpus Striatum | 4 | 2017 | 163 | 0.500 |
Why?
| | Heart Rate | 9 | 2018 | 823 | 0.480 |
Why?
| | Drug Users | 1 | 2015 | 39 | 0.470 |
Why?
| | Coronary Disease | 1 | 2018 | 385 | 0.470 |
Why?
| | Cognitive Dysfunction | 1 | 2020 | 385 | 0.470 |
Why?
| | Gastrointestinal Microbiome | 2 | 2020 | 696 | 0.460 |
Why?
| | Brain-Derived Neurotrophic Factor | 6 | 2015 | 133 | 0.460 |
Why?
| | Interview, Psychological | 2 | 2011 | 95 | 0.450 |
Why?
| | Anxiety | 3 | 2024 | 1032 | 0.450 |
Why?
| | Photic Stimulation | 5 | 2014 | 241 | 0.440 |
Why?
| | Prefrontal Cortex | 3 | 2014 | 304 | 0.440 |
Why?
| | Cerebrum | 1 | 2013 | 7 | 0.440 |
Why?
| | Retinal Dehydrogenase | 1 | 2013 | 30 | 0.430 |
Why?
| | Treatment Outcome | 15 | 2017 | 10764 | 0.420 |
Why?
| | Epigenesis, Genetic | 3 | 2013 | 658 | 0.420 |
Why?
| | Chronic Pain | 1 | 2018 | 255 | 0.420 |
Why?
| | Biomedical Research | 1 | 2019 | 689 | 0.400 |
Why?
| | alpha-Synuclein | 1 | 2013 | 34 | 0.400 |
Why?
| | Receptors, Neurokinin-1 | 1 | 2012 | 9 | 0.400 |
Why?
| | Body Weight | 1 | 2017 | 981 | 0.400 |
Why?
| | Pirenzepine | 2 | 2003 | 7 | 0.400 |
Why?
| | Genome-Wide Association Study | 3 | 2016 | 1434 | 0.390 |
Why?
| | Models, Psychological | 6 | 2011 | 307 | 0.390 |
Why?
| | Analysis of Variance | 12 | 2012 | 1318 | 0.380 |
Why?
| | Attention | 4 | 2020 | 435 | 0.380 |
Why?
| | Aging | 4 | 2022 | 1861 | 0.380 |
Why?
| | Mouth | 2 | 2024 | 86 | 0.370 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2011 | 45 | 0.370 |
Why?
| | Secondary Prevention | 2 | 2023 | 233 | 0.370 |
Why?
| | Receptor, Muscarinic M2 | 1 | 2011 | 9 | 0.370 |
Why?
| | Dose-Response Relationship, Drug | 9 | 2015 | 2045 | 0.370 |
Why?
| | Personality | 2 | 2006 | 130 | 0.370 |
Why?
| | Cytidine Deaminase | 1 | 2011 | 61 | 0.360 |
Why?
| | Cytokines | 3 | 2025 | 2088 | 0.360 |
Why?
| | Pharmacogenetics | 2 | 2010 | 179 | 0.350 |
Why?
| | Protons | 1 | 2011 | 90 | 0.350 |
Why?
| | Surveys and Questionnaires | 19 | 2013 | 5749 | 0.350 |
Why?
| | Extinction, Psychological | 1 | 2012 | 85 | 0.350 |
Why?
| | Limbic System | 2 | 2008 | 47 | 0.350 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2011 | 100 | 0.330 |
Why?
| | Intelligence | 1 | 2011 | 130 | 0.330 |
Why?
| | Gene Deletion | 1 | 2011 | 392 | 0.330 |
Why?
| | Gene Expression | 3 | 2010 | 1499 | 0.320 |
Why?
| | Alleles | 6 | 2011 | 888 | 0.320 |
Why?
| | Students | 3 | 2011 | 624 | 0.320 |
Why?
| | Text Messaging | 1 | 2012 | 156 | 0.320 |
Why?
| | Choice Behavior | 1 | 2011 | 171 | 0.320 |
Why?
| | Personality Inventory | 5 | 2011 | 141 | 0.320 |
Why?
| | Connectome | 3 | 2024 | 85 | 0.310 |
Why?
| | Psychotherapy, Group | 1 | 2009 | 66 | 0.310 |
Why?
| | Genomics | 2 | 2012 | 790 | 0.310 |
Why?
| | Diabetes Mellitus | 1 | 2018 | 1033 | 0.310 |
Why?
| | Proteins | 2 | 2013 | 1009 | 0.310 |
Why?
| | Avoidance Learning | 1 | 2009 | 76 | 0.300 |
Why?
| | Genetic Linkage | 1 | 2009 | 298 | 0.290 |
Why?
| | Alcohol-Induced Disorders, Nervous System | 1 | 2007 | 6 | 0.290 |
Why?
| | Breath Tests | 5 | 2009 | 87 | 0.280 |
Why?
| | Depression | 2 | 2024 | 1402 | 0.280 |
Why?
| | Image Processing, Computer-Assisted | 8 | 2016 | 752 | 0.280 |
Why?
| | Methylation | 2 | 2018 | 231 | 0.280 |
Why?
| | Alcohols | 1 | 2007 | 29 | 0.280 |
Why?
| | Obesity | 2 | 2018 | 2975 | 0.270 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2024 | 1455 | 0.270 |
Why?
| | Counseling | 1 | 2011 | 391 | 0.270 |
Why?
| | Infusions, Intravenous | 4 | 2018 | 408 | 0.270 |
Why?
| | Drug Resistance | 1 | 2007 | 169 | 0.270 |
Why?
| | Acoustic Stimulation | 3 | 2013 | 316 | 0.260 |
Why?
| | Health Education | 1 | 2009 | 337 | 0.260 |
Why?
| | Mental Health | 2 | 2025 | 721 | 0.250 |
Why?
| | Hydrocortisone | 1 | 2008 | 317 | 0.250 |
Why?
| | Case-Control Studies | 10 | 2017 | 3537 | 0.250 |
Why?
| | Sex Factors | 8 | 2021 | 2068 | 0.250 |
Why?
| | Lipoxygenase | 1 | 2025 | 18 | 0.240 |
Why?
| | Physical Fitness | 2 | 2020 | 209 | 0.240 |
Why?
| | Organ Size | 5 | 2018 | 477 | 0.240 |
Why?
| | Diagnostic Imaging | 1 | 2008 | 331 | 0.240 |
Why?
| | Microbiota | 3 | 2024 | 761 | 0.240 |
Why?
| | Homosexuality, Female | 1 | 2005 | 39 | 0.240 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2025 | 77 | 0.240 |
Why?
| | Program Evaluation | 1 | 2009 | 886 | 0.240 |
Why?
| | Self Concept | 1 | 2007 | 252 | 0.240 |
Why?
| | Genetic Association Studies | 5 | 2015 | 376 | 0.230 |
Why?
| | Body Mass Index | 4 | 2020 | 2364 | 0.230 |
Why?
| | Helplessness, Learned | 1 | 2005 | 68 | 0.230 |
Why?
| | Adolescent Behavior | 3 | 2021 | 534 | 0.230 |
Why?
| | CpG Islands | 2 | 2016 | 159 | 0.230 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2025 | 158 | 0.230 |
Why?
| | Patient-Centered Care | 1 | 2010 | 520 | 0.220 |
Why?
| | Social Perception | 1 | 2005 | 107 | 0.220 |
Why?
| | Depressive Disorder, Major | 2 | 2024 | 360 | 0.220 |
Why?
| | Homosexuality, Male | 1 | 2005 | 182 | 0.220 |
Why?
| | Genome, Human | 3 | 2012 | 424 | 0.220 |
Why?
| | Tobacco Use | 1 | 2024 | 65 | 0.210 |
Why?
| | Anti-Anxiety Agents | 1 | 2024 | 46 | 0.210 |
Why?
| | Dopamine Uptake Inhibitors | 2 | 2003 | 59 | 0.210 |
Why?
| | Alcohol Abstinence | 2 | 2014 | 12 | 0.210 |
Why?
| | Aspartic Acid | 3 | 2012 | 82 | 0.210 |
Why?
| | Schizophrenia | 2 | 2025 | 439 | 0.210 |
Why?
| | Habituation, Psychophysiologic | 1 | 2003 | 55 | 0.200 |
Why?
| | Chi-Square Distribution | 4 | 2012 | 532 | 0.200 |
Why?
| | Cross-Over Studies | 2 | 2023 | 560 | 0.200 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2022 | 50 | 0.190 |
Why?
| | Cognition | 3 | 2011 | 1166 | 0.190 |
Why?
| | Sequence Analysis, DNA | 2 | 2020 | 811 | 0.190 |
Why?
| | Central Nervous System Stimulants | 2 | 2004 | 161 | 0.190 |
Why?
| | Phosphocreatine | 2 | 2012 | 47 | 0.190 |
Why?
| | Psychotic Disorders | 1 | 2024 | 167 | 0.190 |
Why?
| | Creatine | 2 | 2012 | 60 | 0.190 |
Why?
| | Homozygote | 2 | 2012 | 203 | 0.180 |
Why?
| | Cannabinoid Receptor Agonists | 1 | 2021 | 46 | 0.180 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2024 | 549 | 0.180 |
Why?
| | Individuality | 5 | 2011 | 162 | 0.180 |
Why?
| | Blood Pressure | 5 | 2018 | 1772 | 0.180 |
Why?
| | Harm Reduction | 1 | 2021 | 39 | 0.180 |
Why?
| | Psychiatric Status Rating Scales | 4 | 2011 | 548 | 0.180 |
Why?
| | Frontal Lobe | 2 | 2013 | 150 | 0.170 |
Why?
| | Inflammation | 2 | 2025 | 2834 | 0.170 |
Why?
| | Hippocampus | 3 | 2021 | 895 | 0.170 |
Why?
| | Cerebellar Cortex | 1 | 2021 | 21 | 0.170 |
Why?
| | Axons | 2 | 2013 | 199 | 0.170 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2239 | 0.170 |
Why?
| | Endocannabinoids | 1 | 2021 | 63 | 0.170 |
Why?
| | Colorado | 4 | 2021 | 4491 | 0.170 |
Why?
| | Verbal Learning | 1 | 2020 | 65 | 0.170 |
Why?
| | Dextroamphetamine | 1 | 1999 | 2 | 0.160 |
Why?
| | Promoter Regions, Genetic | 2 | 2018 | 1250 | 0.160 |
Why?
| | Glutamic Acid | 2 | 2012 | 248 | 0.160 |
Why?
| | Support Vector Machine | 2 | 2018 | 38 | 0.160 |
Why?
| | Alcohol Deterrents | 2 | 2018 | 18 | 0.160 |
Why?
| | DNA Mutational Analysis | 3 | 2012 | 400 | 0.160 |
Why?
| | Dopamine and cAMP-Regulated Phosphoprotein 32 | 2 | 2011 | 9 | 0.160 |
Why?
| | Drug and Narcotic Control | 1 | 2019 | 28 | 0.160 |
Why?
| | Sexual Behavior | 2 | 2021 | 485 | 0.160 |
Why?
| | Knowledge | 1 | 2019 | 53 | 0.160 |
Why?
| | Brain Chemistry | 2 | 2011 | 118 | 0.160 |
Why?
| | Sympathomimetics | 1 | 1999 | 21 | 0.160 |
Why?
| | Comorbidity | 2 | 2018 | 1611 | 0.160 |
Why?
| | Health Behavior | 3 | 2013 | 756 | 0.160 |
Why?
| | Amphetamine | 1 | 1999 | 34 | 0.150 |
Why?
| | Risk Reduction Behavior | 1 | 2021 | 218 | 0.150 |
Why?
| | Juvenile Delinquency | 2 | 2013 | 109 | 0.150 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2021 | 591 | 0.150 |
Why?
| | Cross-Sectional Studies | 5 | 2017 | 5417 | 0.150 |
Why?
| | Neuropsychological Tests | 6 | 2018 | 1054 | 0.150 |
Why?
| | Pain | 1 | 2024 | 755 | 0.150 |
Why?
| | Cocaine-Related Disorders | 2 | 2018 | 113 | 0.150 |
Why?
| | Underage Drinking | 1 | 2018 | 22 | 0.140 |
Why?
| | Environment | 2 | 2010 | 362 | 0.140 |
Why?
| | Placebo Effect | 1 | 2017 | 24 | 0.140 |
Why?
| | Postural Balance | 1 | 2020 | 212 | 0.140 |
Why?
| | Speech | 2 | 2012 | 73 | 0.140 |
Why?
| | Mass Spectrometry | 1 | 2021 | 739 | 0.140 |
Why?
| | Benzazepines | 1 | 2017 | 39 | 0.140 |
Why?
| | Dysbiosis | 1 | 2019 | 180 | 0.140 |
Why?
| | Tobacco Smoking | 1 | 2017 | 28 | 0.140 |
Why?
| | Southwestern United States | 1 | 2017 | 90 | 0.140 |
Why?
| | Pilot Projects | 5 | 2019 | 1697 | 0.140 |
Why?
| | Information Dissemination | 1 | 2019 | 217 | 0.140 |
Why?
| | Research Design | 3 | 2019 | 1107 | 0.140 |
Why?
| | Biomarkers | 3 | 2021 | 4158 | 0.130 |
Why?
| | Gene Frequency | 3 | 2008 | 520 | 0.130 |
Why?
| | Beverages | 1 | 2017 | 69 | 0.130 |
Why?
| | Interleukin-8 | 1 | 2018 | 267 | 0.130 |
Why?
| | Insulin Resistance | 1 | 2025 | 1201 | 0.130 |
Why?
| | Amygdala | 2 | 2021 | 191 | 0.130 |
Why?
| | Food Preferences | 1 | 2017 | 119 | 0.120 |
Why?
| | Reaction Time | 2 | 2011 | 416 | 0.120 |
Why?
| | Exercise Therapy | 1 | 2020 | 434 | 0.120 |
Why?
| | Interleukin-1beta | 1 | 2018 | 372 | 0.120 |
Why?
| | Age Factors | 2 | 2013 | 3290 | 0.120 |
Why?
| | Behavior | 2 | 2009 | 90 | 0.120 |
Why?
| | Proton Magnetic Resonance Spectroscopy | 1 | 2015 | 21 | 0.120 |
Why?
| | Follow-Up Studies | 4 | 2013 | 5115 | 0.120 |
Why?
| | Placebos | 3 | 2007 | 197 | 0.120 |
Why?
| | Hypnotics and Sedatives | 2 | 2009 | 199 | 0.120 |
Why?
| | Public Policy | 1 | 2015 | 82 | 0.120 |
Why?
| | Models, Neurological | 2 | 2015 | 243 | 0.120 |
Why?
| | Radiography | 2 | 2015 | 829 | 0.120 |
Why?
| | Animals | 8 | 2019 | 36768 | 0.110 |
Why?
| | Legislation, Drug | 1 | 2015 | 81 | 0.110 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2015 | 145 | 0.110 |
Why?
| | Signal Transduction | 3 | 2019 | 5065 | 0.110 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 2 | 2012 | 75 | 0.110 |
Why?
| | Energy Intake | 1 | 2017 | 484 | 0.110 |
Why?
| | Drug Interactions | 2 | 2007 | 405 | 0.110 |
Why?
| | Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2013 | 26 | 0.110 |
Why?
| | Statistics, Nonparametric | 1 | 2015 | 430 | 0.110 |
Why?
| | United States | 6 | 2019 | 14660 | 0.110 |
Why?
| | Interleukin-6 | 1 | 2018 | 778 | 0.100 |
Why?
| | Nerve Tissue Proteins | 2 | 2010 | 596 | 0.100 |
Why?
| | Bacteria | 1 | 2020 | 855 | 0.100 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2013 | 29 | 0.100 |
Why?
| | Basal Ganglia | 1 | 2013 | 56 | 0.100 |
Why?
| | Sample Size | 1 | 2013 | 117 | 0.100 |
Why?
| | Adaptation, Psychological | 2 | 2011 | 651 | 0.100 |
Why?
| | Factor Analysis, Statistical | 2 | 2015 | 286 | 0.100 |
Why?
| | Stress Disorders, Traumatic | 1 | 2013 | 23 | 0.100 |
Why?
| | Nerve Fibers, Unmyelinated | 1 | 2012 | 9 | 0.100 |
Why?
| | Nucleus Accumbens | 2 | 2021 | 138 | 0.100 |
Why?
| | Norepinephrine | 1 | 2013 | 204 | 0.100 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2017 | 422 | 0.100 |
Why?
| | Models, Genetic | 2 | 2007 | 605 | 0.100 |
Why?
| | Receptors, Serotonin | 1 | 2012 | 34 | 0.100 |
Why?
| | Hypothalamo-Hypophyseal System | 2 | 2008 | 197 | 0.100 |
Why?
| | Body Temperature | 1 | 2013 | 220 | 0.100 |
Why?
| | Auditory Perception | 1 | 2013 | 115 | 0.100 |
Why?
| | Reproducibility of Results | 4 | 2023 | 3272 | 0.100 |
Why?
| | Predictive Value of Tests | 2 | 2012 | 2030 | 0.100 |
Why?
| | Cerebrospinal Fluid | 1 | 2012 | 94 | 0.100 |
Why?
| | Glutamine | 1 | 2012 | 104 | 0.100 |
Why?
| | Longitudinal Studies | 3 | 2014 | 2847 | 0.100 |
Why?
| | Lactic Acid | 1 | 2013 | 306 | 0.090 |
Why?
| | Visual Perception | 1 | 2013 | 162 | 0.090 |
Why?
| | Glycerylphosphorylcholine | 1 | 2011 | 6 | 0.090 |
Why?
| | Life Style | 2 | 2012 | 484 | 0.090 |
Why?
| | Inositol | 1 | 2011 | 26 | 0.090 |
Why?
| | Phosphorylcholine | 1 | 2011 | 20 | 0.090 |
Why?
| | Heterozygote | 1 | 2012 | 292 | 0.090 |
Why?
| | Choline | 1 | 2012 | 131 | 0.090 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2011 | 48 | 0.090 |
Why?
| | Gene-Environment Interaction | 1 | 2013 | 194 | 0.090 |
Why?
| | Linear Models | 2 | 2016 | 845 | 0.090 |
Why?
| | Neuroanatomy | 2 | 2021 | 8 | 0.090 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2011 | 23 | 0.090 |
Why?
| | Association | 1 | 2011 | 12 | 0.090 |
Why?
| | Prognosis | 2 | 2017 | 4018 | 0.090 |
Why?
| | Carbon Monoxide | 3 | 2007 | 80 | 0.090 |
Why?
| | Pregnancy Complications | 1 | 1996 | 522 | 0.090 |
Why?
| | Genetic Markers | 1 | 2012 | 344 | 0.090 |
Why?
| | Risk | 2 | 2011 | 904 | 0.090 |
Why?
| | Motivational Interviewing | 1 | 2012 | 103 | 0.090 |
Why?
| | Washington | 1 | 2011 | 154 | 0.090 |
Why?
| | Administration, Cutaneous | 2 | 2007 | 128 | 0.080 |
Why?
| | Brain Diseases | 1 | 2011 | 141 | 0.080 |
Why?
| | Pregnanolone | 1 | 2010 | 37 | 0.080 |
Why?
| | Euphoria | 1 | 2009 | 3 | 0.080 |
Why?
| | Genetic Testing | 2 | 2015 | 452 | 0.080 |
Why?
| | New Mexico | 1 | 2009 | 92 | 0.080 |
Why?
| | gamma-Aminobutyric Acid | 2 | 2010 | 198 | 0.080 |
Why?
| | Oxygen Consumption | 1 | 2013 | 696 | 0.080 |
Why?
| | Professional-Patient Relations | 1 | 2011 | 143 | 0.080 |
Why?
| | Temperance | 1 | 2009 | 13 | 0.080 |
Why?
| | Smoking Prevention | 2 | 2007 | 186 | 0.080 |
Why?
| | Drug Design | 1 | 2010 | 166 | 0.080 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2011 | 616 | 0.080 |
Why?
| | Social Class | 1 | 2011 | 277 | 0.070 |
Why?
| | Life Change Events | 2 | 2010 | 151 | 0.070 |
Why?
| | Methamphetamine | 2 | 2019 | 63 | 0.070 |
Why?
| | Brain Concussion | 1 | 2016 | 568 | 0.070 |
Why?
| | Presynaptic Terminals | 1 | 2009 | 88 | 0.070 |
Why?
| | Probability | 1 | 2009 | 309 | 0.070 |
Why?
| | Opioid-Related Disorders | 1 | 2015 | 504 | 0.070 |
Why?
| | Time Factors | 4 | 2006 | 6792 | 0.070 |
Why?
| | Genetics, Behavioral | 1 | 2007 | 40 | 0.070 |
Why?
| | Gambling | 1 | 2007 | 33 | 0.070 |
Why?
| | DNA Primers | 1 | 2008 | 513 | 0.070 |
Why?
| | Prospective Studies | 3 | 2013 | 7583 | 0.070 |
Why?
| | Risk Factors | 4 | 2013 | 10331 | 0.070 |
Why?
| | Disruptive, Impulse Control, and Conduct Disorders | 1 | 2007 | 11 | 0.070 |
Why?
| | Neostriatum | 1 | 2007 | 33 | 0.070 |
Why?
| | Universities | 1 | 2009 | 432 | 0.070 |
Why?
| | Injections, Intravenous | 1 | 2007 | 205 | 0.070 |
Why?
| | Twins, Dizygotic | 1 | 2007 | 183 | 0.070 |
Why?
| | Electromyography | 2 | 2000 | 401 | 0.060 |
Why?
| | Drinking Behavior | 1 | 2006 | 10 | 0.060 |
Why?
| | Physical Exertion | 2 | 2023 | 215 | 0.060 |
Why?
| | Siblings | 1 | 2007 | 228 | 0.060 |
Why?
| | Twins, Monozygotic | 1 | 2007 | 212 | 0.060 |
Why?
| | Synaptic Transmission | 1 | 2008 | 289 | 0.060 |
Why?
| | Retrospective Studies | 2 | 2015 | 15564 | 0.060 |
Why?
| | Self Efficacy | 1 | 2009 | 394 | 0.060 |
Why?
| | Libido | 1 | 2005 | 24 | 0.060 |
Why?
| | Sensation | 1 | 2006 | 53 | 0.060 |
Why?
| | Health Promotion | 1 | 2012 | 736 | 0.060 |
Why?
| | Heterosexuality | 1 | 2005 | 43 | 0.060 |
Why?
| | Social Values | 1 | 2005 | 36 | 0.060 |
Why?
| | Patient Satisfaction | 1 | 2009 | 650 | 0.060 |
Why?
| | Stereotyping | 1 | 2005 | 45 | 0.060 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2005 | 35 | 0.060 |
Why?
| | Bulimia | 1 | 2005 | 25 | 0.060 |
Why?
| | Depressive Disorder | 1 | 2008 | 380 | 0.060 |
Why?
| | Synapses | 1 | 2009 | 425 | 0.060 |
Why?
| | DNA | 2 | 2010 | 1458 | 0.060 |
Why?
| | Binding Sites | 2 | 2007 | 1308 | 0.060 |
Why?
| | Internal-External Control | 1 | 2005 | 71 | 0.060 |
Why?
| | Rivers | 1 | 2005 | 64 | 0.060 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2005 | 65 | 0.060 |
Why?
| | Rain | 1 | 2005 | 47 | 0.060 |
Why?
| | Appetite | 1 | 2005 | 69 | 0.060 |
Why?
| | Cohort Studies | 3 | 2017 | 5718 | 0.060 |
Why?
| | Problem Solving | 1 | 2005 | 154 | 0.050 |
Why?
| | Ganglionic Stimulants | 1 | 2003 | 14 | 0.050 |
Why?
| | Pleasure | 1 | 2023 | 19 | 0.050 |
Why?
| | Cyproheptadine | 1 | 2003 | 7 | 0.050 |
Why?
| | Disasters | 1 | 2005 | 98 | 0.050 |
Why?
| | Interpersonal Relations | 1 | 2007 | 404 | 0.050 |
Why?
| | Patient Education as Topic | 1 | 2009 | 760 | 0.050 |
Why?
| | Rest | 1 | 2024 | 121 | 0.050 |
Why?
| | Pregnancy | 2 | 1996 | 6731 | 0.050 |
Why?
| | Serotonin Antagonists | 1 | 2003 | 31 | 0.050 |
Why?
| | Bupropion | 1 | 2003 | 45 | 0.050 |
Why?
| | Multimodal Imaging | 1 | 2024 | 116 | 0.050 |
Why?
| | Neural Pathways | 2 | 2016 | 294 | 0.050 |
Why?
| | Physical Stimulation | 1 | 2003 | 65 | 0.050 |
Why?
| | Algorithms | 2 | 2007 | 1686 | 0.050 |
Why?
| | Anisotropy | 2 | 2013 | 79 | 0.050 |
Why?
| | Membrane Transport Proteins | 1 | 2004 | 162 | 0.050 |
Why?
| | Genetics, Population | 1 | 2004 | 210 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2003 | 286 | 0.050 |
Why?
| | Child Behavior | 1 | 2004 | 247 | 0.050 |
Why?
| | Emotions | 1 | 2007 | 546 | 0.050 |
Why?
| | Attitude to Health | 1 | 2005 | 439 | 0.050 |
Why?
| | Models, Theoretical | 1 | 2005 | 572 | 0.050 |
Why?
| | Atmospheric Pressure | 1 | 2021 | 23 | 0.050 |
Why?
| | Running | 1 | 2023 | 230 | 0.040 |
Why?
| | Cognitive Dissonance | 1 | 2001 | 4 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 79 | 0.040 |
Why?
| | Limit of Detection | 1 | 2021 | 86 | 0.040 |
Why?
| | Quality Control | 1 | 2021 | 171 | 0.040 |
Why?
| | Wechsler Scales | 2 | 2012 | 55 | 0.040 |
Why?
| | Boredom | 1 | 1999 | 1 | 0.040 |
Why?
| | Neurons | 1 | 2009 | 1583 | 0.040 |
Why?
| | Personality Tests | 1 | 1999 | 16 | 0.040 |
Why?
| | DNA, Ribosomal | 1 | 2020 | 86 | 0.040 |
Why?
| | Psychophysiology | 1 | 1999 | 13 | 0.040 |
Why?
| | Receptors, Purinergic | 2 | 1990 | 22 | 0.040 |
Why?
| | Conditioning, Classical | 1 | 2000 | 102 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2007 | 2831 | 0.040 |
Why?
| | Autism Spectrum Disorder | 1 | 2024 | 392 | 0.040 |
Why?
| | DNA, Bacterial | 1 | 2020 | 336 | 0.040 |
Why?
| | Quality Indicators, Health Care | 1 | 2021 | 308 | 0.040 |
Why?
| | Thalamus | 2 | 2012 | 107 | 0.040 |
Why?
| | Amphetamine-Related Disorders | 1 | 2018 | 40 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2007 | 2603 | 0.040 |
Why?
| | Blinking | 1 | 1997 | 8 | 0.040 |
Why?
| | Hyperkinesis | 1 | 2017 | 16 | 0.030 |
Why?
| | Cocaine | 1 | 2019 | 165 | 0.030 |
Why?
| | Self Administration | 1 | 2018 | 123 | 0.030 |
Why?
| | Pituitary-Adrenal System | 1 | 1999 | 162 | 0.030 |
Why?
| | Risk Assessment | 1 | 2007 | 3429 | 0.030 |
Why?
| | Pharmacogenomic Testing | 1 | 2018 | 64 | 0.030 |
Why?
| | Electroencephalography | 1 | 2000 | 433 | 0.030 |
Why?
| | Association Learning | 1 | 2017 | 60 | 0.030 |
Why?
| | Central Nervous System Diseases | 1 | 1997 | 69 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 1997 | 216 | 0.030 |
Why?
| | Computer Simulation | 2 | 2015 | 973 | 0.030 |
Why?
| | Volition | 1 | 1996 | 34 | 0.030 |
Why?
| | Sampling Studies | 1 | 1996 | 100 | 0.030 |
Why?
| | Aged | 4 | 2020 | 23729 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 400 | 0.030 |
Why?
| | Self-Assessment | 1 | 1996 | 74 | 0.030 |
Why?
| | Maternal Behavior | 1 | 1996 | 77 | 0.030 |
Why?
| | Pregnancy Trimester, First | 1 | 1996 | 143 | 0.030 |
Why?
| | Conduct Disorder | 1 | 2017 | 201 | 0.030 |
Why?
| | Hemodynamics | 1 | 2000 | 1110 | 0.030 |
Why?
| | Meta-Analysis as Topic | 1 | 2015 | 172 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 1997 | 257 | 0.030 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2015 | 143 | 0.030 |
Why?
| | Athletic Performance | 1 | 2015 | 79 | 0.030 |
Why?
| | Salivation | 2 | 2007 | 4 | 0.030 |
Why?
| | Event-Related Potentials, P300 | 1 | 2013 | 14 | 0.030 |
Why?
| | Drug-Seeking Behavior | 1 | 2013 | 22 | 0.030 |
Why?
| | Data Interpretation, Statistical | 1 | 2015 | 349 | 0.030 |
Why?
| | Carrier Proteins | 2 | 2004 | 768 | 0.030 |
Why?
| | Placenta | 2 | 1990 | 747 | 0.020 |
Why?
| | Evoked Potentials | 1 | 2013 | 126 | 0.020 |
Why?
| | Chronic Disease | 1 | 1999 | 1784 | 0.020 |
Why?
| | Behavioral Symptoms | 1 | 2012 | 42 | 0.020 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2012 | 59 | 0.020 |
Why?
| | Fornix, Brain | 1 | 2012 | 6 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 1058 | 0.020 |
Why?
| | Spatial Analysis | 1 | 2012 | 20 | 0.020 |
Why?
| | Research | 1 | 2015 | 445 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2013 | 495 | 0.020 |
Why?
| | Water | 1 | 2015 | 463 | 0.020 |
Why?
| | Functional Laterality | 1 | 2012 | 223 | 0.020 |
Why?
| | Haplotypes | 1 | 2013 | 490 | 0.020 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2012 | 153 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2012 | 338 | 0.020 |
Why?
| | Luciferases | 1 | 2010 | 150 | 0.020 |
Why?
| | Methods | 1 | 2010 | 65 | 0.020 |
Why?
| | Cerebellum | 1 | 2012 | 224 | 0.020 |
Why?
| | Chromosomes, Human, X | 1 | 2010 | 74 | 0.020 |
Why?
| | Chromosomes | 1 | 2010 | 108 | 0.020 |
Why?
| | Plasmids | 1 | 2010 | 362 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2010 | 195 | 0.020 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 2009 | 36 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 309 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 973 | 0.020 |
Why?
| | Transfection | 1 | 2010 | 945 | 0.020 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2009 | 241 | 0.020 |
Why?
| | Feedback, Psychological | 1 | 2007 | 20 | 0.020 |
Why?
| | Chewing Gum | 1 | 2007 | 9 | 0.020 |
Why?
| | Beer | 1 | 2007 | 12 | 0.020 |
Why?
| | Tablets | 1 | 2007 | 36 | 0.020 |
Why?
| | Capsules | 1 | 2007 | 38 | 0.020 |
Why?
| | Learning | 1 | 2011 | 414 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2019 | 7569 | 0.020 |
Why?
| | Blood Platelets | 1 | 1990 | 405 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1513 | 0.020 |
Why?
| | Child | 2 | 2022 | 21968 | 0.020 |
Why?
| | Demography | 1 | 2007 | 291 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2010 | 1281 | 0.020 |
Why?
| | Body Temperature Regulation | 1 | 2007 | 97 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2012 | 806 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2007 | 311 | 0.020 |
Why?
| | Radar | 1 | 2005 | 1 | 0.020 |
Why?
| | Geographic Information Systems | 1 | 2005 | 43 | 0.010 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2007 | 267 | 0.010 |
Why?
| | Cerebrovascular Circulation | 1 | 2007 | 240 | 0.010 |
Why?
| | Psychometrics | 1 | 2009 | 721 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2009 | 538 | 0.010 |
Why?
| | Geography | 1 | 2005 | 197 | 0.010 |
Why?
| | Texas | 1 | 2005 | 246 | 0.010 |
Why?
| | Administration, Oral | 1 | 2007 | 808 | 0.010 |
Why?
| | Patient Compliance | 1 | 2008 | 576 | 0.010 |
Why?
| | Age Distribution | 1 | 2004 | 391 | 0.010 |
Why?
| | Sex Distribution | 1 | 2004 | 376 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2010 | 4194 | 0.010 |
Why?
| | Speech Production Measurement | 1 | 2002 | 12 | 0.010 |
Why?
| | Parent-Child Relations | 1 | 2004 | 271 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 500 | 0.010 |
Why?
| | Adenosine-5'-(N-ethylcarboxamide) | 2 | 1990 | 11 | 0.010 |
Why?
| | Societies, Medical | 1 | 2004 | 820 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2010 | 4279 | 0.010 |
Why?
| | Databases, Factual | 1 | 2005 | 1347 | 0.010 |
Why?
| | Feeding Behavior | 1 | 2005 | 648 | 0.010 |
Why?
| | Adenosine | 2 | 1990 | 226 | 0.010 |
Why?
| | Prevalence | 1 | 2004 | 2712 | 0.010 |
Why?
| | Immune System | 1 | 1997 | 177 | 0.010 |
Why?
| | Cell Membrane | 2 | 1990 | 736 | 0.010 |
Why?
| | Radioligand Assay | 1 | 1990 | 48 | 0.010 |
Why?
| | Tritium | 1 | 1990 | 76 | 0.010 |
Why?
| | 2-Chloroadenosine | 1 | 1989 | 3 | 0.000 |
Why?
| | Guanylyl Imidodiphosphate | 1 | 1989 | 5 | 0.000 |
Why?
| | Guanine Nucleotides | 1 | 1989 | 14 | 0.000 |
Why?
| | Vasodilator Agents | 1 | 1990 | 331 | 0.000 |
Why?
| | Kinetics | 1 | 1989 | 1668 | 0.000 |
Why?
|
|
Hutchison's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|